A Randomized Phase II Study Evaluating Upfront SRT to All Brain Metastases Followed by Ivonescimab Plus Chemotherapy Versus Upfront Ivonescimab Plus Chemotherapy in Patients With Asymptomatic Active Brain Metastases From NSCLC

NCT07234877 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

158

Enrollment

NETWORK

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: ivonescimab

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC

Collaborators

[object Object]